EXELIXIS, INC. Q3 FY2026 earnings call

• Strategic Focus: Management is laser-focused on advancing XL (Zanzalintinib/ZANSA) to become a major oncology franchise, supported by the strong performance of the existing Cabo franchise.
• Cabo Performance: Cabo continues to show robust growth, driven by strength in both Renal Cell Carcinoma (RCC) and Neuroendocrine Tumors (NET). It remains the number one prescribed TKI plus IO combination in RCC and the number one oral therapy in the second-line-plus NET setting.
• ZANSA Development Pipeline: ZANSA is the top R&D priority. Seven 'Wave 1' pivotal trials are ongoing, with plans for 'Wave 2' studies exploring combinations with immunotherapies and chemotherapies.
• Key Trial Updates:
  • STELR 316 (CRC adjuvant): Sites activated and enrolling; uses Signatera test for patient selection.
  • STELR 304 (Non-clear cell RCC): Enrollment completed; top-line results expected in Q1 2027.
  • STELR 311 (NET): Robust enrollment in global phase 3 trial against Everolimus.
  • LightSpark 033/034 (Clear cell RCC): Ongoing Phase 3 studies with Merck evaluating ZANSA + Belzutolifan.
  • STELR 202 (Lung Cancer): Initiated enrolling participants in squamous NSCLC maintenance setting.
• Capital Allocation: The company returned $250 million to shareholders via stock repurchases in Q3 2026. Remaining authorization under the $750 million plan is approximately $348 million.
• Operational Efficiency: Gross-to-net deductions were lower in Q3 due to reduced 340B discounts, though full-year guidance has been adjusted upward slightly to reflect updated estimates.

The company reported total revenues of approximately $659 million for the third quarter of 2026. The Cabo franchise was the primary revenue driver, with U.S. net product revenues growing approximately 11% year-over-year to $605 million. Global Cabo franchise net product revenues, including partner sales, grew approximately 11% year-over-year to $818 million. Additionally, the company earned approximately $52 million in royalties from partners Ipsen and Takeda on Cabo Zantes sales. The Cabo Medics franchise maintained its position as the leading TKI for RCC and the market leader for the Oral Second Line Plus NET segment.

• Full Year 2026 Guidance: Management updated the full-year 2026 financial guidance, reflecting changes to cost of goods sold and tax rate estimates.
• Gross-to-Net Deductions: Updated estimate for full-year 2026 gross-to-net deductions is now projected at approximately 30%, up from previous quarters due to seasonal variations but offset by lower 340B discounts in Q3.
• Tax Rate: Effective tax rate expectations have shifted due to the resolution of prior period tax items after the October filing deadline; long-term expectation is near the federal rate.
• Revenue Growth: Cabo franchise revenue growth trajectory remains positive, with Q3 U.S. net product revenues growing ~11% YoY.

• Regulatory Uncertainty: Delays or failures in pivotal trials (e.g., STELR 304, STELR 316) could impact NDA filings and commercial timelines.
• Market Competition: Intense competition in RCC and CRC markets, including emerging therapies like bispecifics and ADCs, may affect market share.
• Clinical Trial Execution: Risks associated with patient enrollment, event rates, and data readouts in ongoing trials, particularly in complex indications like non-clear cell RCC and adjuvant CRC.
• Commercial Launch Risks: Potential challenges in launching ZANSA in community settings despite strong prescriber overlap with Cabo.
• Financial Risks: Fluctuations in gross-to-net deductions, tax rate variability, and dependence on collaboration partners for royalty income.

Q: Analyst asked about the impact of the 340B program evolution on the Cabo franchise and future ZANSA launch. / A: CEO Mike Morrissey stated that 340B has very little impact on Exelixis currently due to their integrity agreement tracking claims and reducing double-counting. He noted that the market access team is actively monitoring the situation, but business stability is being observed, and it remains a focus area without material disruption to current operations.

Q: Analyst inquired about the size of the LightSpark 034 opportunity in clear cell RCC relative to other studies and the impact of recent adjuvant approvals. / A: EVP PJ Haley explained that LightSpark 034 evaluates ZANSA combined with Belzutolifan in the second-line-plus setting, which is differentiated from other studies. While more adjuvant options mean more patients treated overall, the specific design of 034 targets a substantial population in kidney cancer where Exelixis has proven success, positioning it for potential significant business impact if data is positive.

Q: Analyst asked how the metastatic CRC opportunity compares to the adjuvant CRC opportunity (STELR 316) for ZANSA in terms of long-term contribution. / A: EVP PJ Haley highlighted that the metastatic third-line-plus CRC setting represents a $1.5 billion TAM with 23,000 U.S. patients and significant unmet need. In contrast, the adjuvant STELR 316 population involves patients with molecular residual disease who recur quickly (6-8 months), offering a meaningful opportunity to prolong disease-free survival with potentially long therapy duration, though data is still pending.

Q: Analyst questioned the protocol details of STELR 304 regarding OS analysis and potential confounding factors if patients cross over to PD-1 TKIs. / A: EVP Dana Aftab emphasized that STELR 304 is the first randomized Phase 3 trial in this setting, providing level-one evidence for high-unmet-need patients. She confirmed excitement about delivering robust clinical data but did not provide specific technical details on censoring rules or crossover impacts during the call, focusing instead on the study's strategic importance for establishing standard of care.

Q: Analyst asked about the dose selection strategy for ZANSA across different Wave 1 and Wave 2 trials. / A: EVP Dana Aftab explained that dose selection is indication-specific and depends on extensive modeling of exposure-response relationships, tumor type, line of therapy, and combination partners. She declined to disclose specific doses for upcoming trials, noting that each case requires individual evaluation to balance safety and efficacy based on the unique context of each study.